Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

NICE recommends tests to detect lung cancer mutation

NICE recommends tests to detect lung cancer mutation These include Boehringer Ingelheim's Giotrif/ Gilotrif (afatinib) and Roche's Tarceva (erlotinib), both of which have specific approvals for use in patients with EGFR. ... Both medicines were also approved by the US Food and Drug Administration (FDA)

Intellectual property threats in the BRIC markets

Intellectual property threats in the BRIC markets of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.

Boehringer breaks into oncology with FDA approval

Boehringer breaks into oncology with FDA approval Roche and Astellas also received fast-track status in January for their cancer drug Tarceva to cover first-line treatment of NSCLC, receiving approval for this expanded indication in March. ... Like Tarceva (erlotinib),  Gilotrif is also an EGFR

NICE knocks back Lilly’s Alimta in new setting

NICE knocks back Lilly’s Alimta in new setting In June 2011 the Institute rejected Roche's NSCLC drug Tarceva in a maintenance setting because of uncertainty over how long it is able to extend survival.

Interview: Kay Drake and Naoki Okamura, Astellas

Interview: Kay Drake and Naoki Okamura, Astellas The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications

[ Previous 5 results ] 9 10 11 12 13 14 15 16 17 18 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics